CEBPA双突变急性髓系白血病基因调控网络的鉴定与研究
本研究整合基因表达、开放染色质、ChIP和启动子捕获Hi-C数据,定义了所有CEBPA双突变(CEBPAN/C)急性髓系白血病患者共有的核心基因调控网络,鉴定突变C/EBPα蛋白在原代细胞中的结合位点,并显示C/EBPα、AP-1因子和RUNX1共定位且为白血病维持所必需,单细胞实验将网络节点与白血病干细胞向原始细胞的分化轨迹相联系。
要点
- CEBPAN/C急性髓系白血病存在共有的核心基因调控网络。
- 突变C/EBPα、AP-1因子和RUNX1共定位且为白血病维持所必需。
- 该资源可预测该亚型在人类细胞中的特异性治疗脆弱性。
核心结论
- 本研究提供了预测CEBPAN/C急性髓系白血病在人类细胞中特异性治疗脆弱性的重要资源。
研究设计与样本
- 本研究整合基因表达、开放染色质和ChIP数据与启动子捕获Hi-C数据,定义CEBPAN/C急性髓系白血病共有的核心基因调控网络。
- 研究鉴定突变C/EBPα蛋白在原代细胞中的结合位点,并采用单细胞实验连接网络节点与白血病干细胞向原始细胞的分化轨迹。
主要发现
- CEBPAN/C突变破坏髓系生成主要调节因子的结构。
- C/EBPα、AP-1因子和RUNX1共定位,且为急性髓系白血病维持所必需。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Acute myeloid leukemia (AML) is a heterogeneous hematological malignancy caused by mutations in genes encoding transcriptional and epigenetic regulators together with signaling genes. It is characterized by a disturbance of differentiation and abnormal proliferation of hematopoietic progenitors. We have previously shown that each AML subtype establishes its own core gene regulatory network (GRN), consisting of transcription factors binding to their target genes and imposing a specific gene expression pattern that is required for AML maintenance. In this study, we integrate gene expression, open chromatin and ChIP data with promoter-capture Hi-C data to define a refined core GRN common to all patients with CEBPA-double mutant (CEBPAN/C) AML. These mutations disrupt the structure of a major regulator of myelopoiesis. We identify the binding sites of mutated C/EBPα proteins in primary cells, we show that C/EBPα, AP-1 factors and RUNX1 colocalize and are required for AML maintenance, and we employ single cell experiments to link important network nodes to the specific differentiation trajectory from leukemic stem to blast cells. Taken together, our study provides an important resource which predicts the specific therapeutic vulnerabilities of this AML subtype in human cells.
引用
- Adamo A, Chin P, Keane P, et al. Identification and interrogation of the gene regulatory network of CEBPA-double mutant acute myeloid leukemia. Leukemia. 2022. PMID: 36333583. doi:10.1038/s41375-022-01744-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。